Chromocure, Inc. Receives Trading Symbol and Issues Investor Guidance

RENO, NV--(Marketwire - July 09, 2009) -

Highlighted Links

MacReport Media Publishing

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it received its ticker symbol and initiates its business plan accordingly. The company has completed the corporate action review process with FINRA. No reverse-split of the company's stock occurred as part of the company's recent restructuring and corporate action. All stockholders retain the same number of shares they owned prior to the company's re-structuring. The following press release outlines various items to be executed by the Company in the coming days and weeks.

The company intends to execute and timely update investors on the following:

--  Total elimination of prior corporate debt and addition of new
    technology assets.
    
--  Full activation of the Company on the OTC Disclosure Service to
    provide transparency and regular public information.  This will also remove
    the unwanted "Caveat Emptor" flag associated with the company's prior
    operations.
    
--  Investors will be updated on new appointments of MD's and other
    industry professionals to the Company's Advisory and Business Development
    Boards.
    
--  Guidance on 2009 revenues and sales projections.
    
--  New additions to the Company's pathology and cancer labs revenue
    partners
    
--  New installations of the Company's Chromosomal Scanner
    
--  New technology and vendor agreements for national joint venture
    marketing and sales
    
--  Full business plan information and regular technology briefings on the
    company's cancer detection technologies
    

About Us

ChromoCure develops and provides cancer detection systems to diagnostic labs. The systems are provided by the Company and installed on a revenue sharing basis. The Company's systems measure the unique genomic characteristic common to all cancers. This characteristic is never found in normal cells. The Company believes its detection technology has an effective accuracy of 100% for all cancers at all stages. The Company also applies its science and technology to non-toxic and non-invasive approaches to cancer therapy and cure research. Web: http://www.chromocure.com

Safe-Harbor Statement

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's website version of this press release contains various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.